Below are current clinical trials.9 studies in Bladder cancer
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to characterize the immune markers of granulocytes, lymphocytes and monocytes in peripheral blood of newly diagnosed bladder cancer patients.
The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult patients with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.
The primary objective of this study is to evaluate the performance of the methylation marker
panel for the detection of bladder cancer in patients with gross or microscopic hematuria.
The secondary objective is to evaluate the predictive accuracy of a risk model including clinical
factors such as age, gender, smoking history, and presence of gross versus microscopic hematuria compared to a model incorporating the same risk factors along with the methylation
The purpose of this study is to assess how well gemcitabine hydrochloride, cisplatin, and AGS-003-BLD work together for treating patients who have bladder cancer that has spread to the muscle and who are undergoing bladder removal surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. Giving gemcitabine hydrochloride, cisplatin, and AGS-003-BLD together before surgery may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery.
The purpose of this study is to expand previous observations by using a high dose of Instiladrin in patients that are "BCG unresponsive" which refers to patients with high grade non-muscle invasive bladder cancer who are believed to be unlikely to benefit from and should not receive further intravesical BCG.
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.
The goal of this study is to create and maintain a comprehensive genitourinary disease biospecimens bank consisting of tissue, kidney stones and bodily fluid (such as blood or urine, but not limited to this) samples.
The purpose of this study is to evaluate nab-paclitaxel as maintenance therapy after cisplatin-based chemotherapy and surgery in treating patients with high-risk bladder cancer. Maintenance therapy, such as paclitaxel albumin-stabilized nanoparticle formulation, can help keep cancer from coming back after it has disappeared following initial chemotherapy.
The purpose of this study is to evaluate the feasibility of perioperative electronic physical activity monitor use in a surgical population.
June 23, 2017
- SEER stat fact sheets: Bladder cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed Dec. 27, 2016.
- Cancer facts and figures 2016. American Cancer Society. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2016/index. Accessed Dec. 27, 2016.
- Niederhuber JE, et al., eds. Bladder cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed Dec. 1, 2016.
- Bladder and other urothelial cancers screening (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/screening/bladder/healthprofessional. Accessed Dec. 1, 2016.
- Bladder cancer treatment (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/bladder/healthprofessional. Accessed Dec. 1, 2016.
- Lotan Y, et al. Clinical presentation, diagnosis and staging of bladder cancer. http://www.uptodate.com/home. Accessed Dec. 13, 2016.
- What is bladder cancer? American Cancer Society. http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-what-is-bladder-cancer. Accessed Dec. 1, 2016.
- Wein AJ, et al., eds. Tumors of the bladder. In: Campbell-Walsh Urology. 11th ed. Philadelphia, Pa.: Elsevier; 2016. http://www.clinicalkey.com. Accessed Dec. 29, 2016.
- Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. Linthicum, Md.: American Urological Association. https://www.auanet.org/education/guidelines/non-muscle-invasive-bladder-cancer.cfm. Accessed Dec. 29, 2016.
- Tumor grade. National Cancer Institute. https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet. Accessed March 13, 2017.
- Lerner SP, et al. Overview of the initial approach and management of urothelial bladder cancer. http://www.uptodate.com/home. Accessed Dec. 13, 2016.
- Wein AJ, et al., eds. Non-muscle-invasive bladder (Ta, T1, and CIS). In: Campbell-Walsh Urology. 11th ed. Philadelphia, Pa.: Elsevier; 2016. http://www.clinicalkey.com. Accessed Dec. 1, 2016.
- Wein AJ, et al., eds. Management of metastatic and invasive bladder cancer. In: Campbell-Walsh Urology. 11th ed. Philadelphia, Pa.: Elsevier; 2016. http://www.clinicalkey.com. Accessed Dec. 1, 2016.
- Clark PE, et al. NCCN guidelines insights: Bladder cancer, version 2.2016. Journal of the National Comprehensive Cancer Network. 2016;14:1213.
- Brown AY. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Oct. 27, 2016.
- What are the grades and stages of bladder cancer? Urology Care Foundation. http://www.urologyhealth.org/urologic-conditions/bladder-cancer/grading-and-staging. Accessed March 13, 2017.
- Premo C, et al. Trimodality therapy in bladder cancer: Who, what and when? The Urologic Clinics of North America. 2015;42:169.
- Efstathiou JA, et al. Bladder preservation treatment options for muscle-invasive urothelial bladder cancer. http://www.uptodate.com/home. Accessed March 14, 2017.
- How is upper urinary tract cancer treated? Urology Care Foundation. http://www.urologyhealth.org/urologic-conditions/upper-urinary-tract-cancer/treatment. Accessed March 14, 2017.
- Bellmunt J. Treatment of metastatic urothelial cancer of the bladder and urinary tract. http://www.uptodate.com/home. Accessed March 28, 2017.